12:00 AM
Nov 22, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Darvon regulatory update

Xanodyne will withdraw its propoxyphene-containing pain drugs at FDA's request after new data showed the drugs increase the risk for serious abnormal heart rhythms. A new safety study...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >